Agilent Technologies, Inc. (A) Stake Cut by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL decreased its stake in Agilent Technologies, Inc. (NYSE:A) by 11.9% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 145,400 shares of the medical research company’s stock after selling 19,600 shares during the period. Gamco Investors INC. ET AL’s holdings in Agilent Technologies were worth $8,624,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Agilent Technologies by 1,946.9% in the first quarter. BlackRock Inc. now owns 23,119,219 shares of the medical research company’s stock valued at $1,222,310,000 after buying an additional 21,989,739 shares during the last quarter. FMR LLC boosted its stake in Agilent Technologies by 3.9% in the first quarter. FMR LLC now owns 21,588,407 shares of the medical research company’s stock valued at $1,141,379,000 after buying an additional 803,993 shares during the last quarter. Vanguard Group Inc. boosted its stake in Agilent Technologies by 0.4% in the first quarter. Vanguard Group Inc. now owns 21,455,971 shares of the medical research company’s stock valued at $1,134,378,000 after buying an additional 75,886 shares during the last quarter. State Street Corp boosted its stake in Agilent Technologies by 1.0% in the first quarter. State Street Corp now owns 14,457,425 shares of the medical research company’s stock valued at $764,348,000 after buying an additional 147,518 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Agilent Technologies by 31.4% in the first quarter. JPMorgan Chase & Co. now owns 8,366,511 shares of the medical research company’s stock valued at $442,338,000 after buying an additional 1,999,376 shares during the last quarter.

Agilent Technologies, Inc. (NYSE A) opened at 61.74 on Tuesday. The stock has a market cap of $19.88 billion, a price-to-earnings ratio of 31.84 and a beta of 1.30. Agilent Technologies, Inc. has a 1-year low of $42.92 and a 1-year high of $62.42. The stock has a 50 day moving average of $60.37 and a 200 day moving average of $56.33.

Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the business earned $0.49 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Equities analysts expect that Agilent Technologies, Inc. will post $2.31 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by [[site]] and is owned by of [[site]]. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at [[permalink]].

Several equities research analysts recently issued reports on A shares. Robert W. Baird raised their price objective on shares of Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 24th. Jefferies Group LLC restated a “buy” rating and set a $66.00 price objective on shares of Agilent Technologies in a research report on Wednesday, August 9th. Morgan Stanley raised their price objective on shares of Agilent Technologies from $65.00 to $70.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 24th. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a research report on Tuesday, May 16th. Finally, BidaskClub lowered shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Agilent Technologies has an average rating of “Buy” and a consensus price target of $63.18.

In other news, Director Paul N. Clark sold 3,866 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $59.05, for a total transaction of $228,287.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James Cullen sold 15,482 shares of the business’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $59.04, for a total value of $914,057.28. The disclosure for this sale can be found here. Insiders have sold a total of 88,036 shares of company stock valued at $5,315,704 in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.